Analysis of 35,213 patients with stage II-III colon cancer revealed that recurrence risk drops below 0.5% at 6 years post-surgery, supporting a practical definition of cure. Women showed a ...
Pfizer PFE is one of the leading oncology drugmakers with a strong presence across breast, genitourinary, thoracic, gastrointestinal and blood cancers. The company has a well-established portfolio of ...
Among breast cancer survivors, the risk of developing a different type of cancer is only about 2 percent higher than the general population, according to a new study of women diagnosed between 1993 ...
Stage 2 prostate adenocarcinoma is localized, with a nearly 100%, five-year relative survival rate. Diagnosis uses the TNM system, PSA levels and Gleason score to determine cancer stage and risk.
A new study found that women’s risk for lung, uterine, or other cancers is only slightly higher for breast cancer survivors compared with the general population. Among breast cancer survivors, the ...